Uncategorized
FDA adds ocular indication for Humira, issues complete response letters
Recent FDA activity includes the addition of an ocular indication for AbbVie’s Humira and the issuance of two complete response letters, one to Ocular Therapeutix and one to Valeant, citing manufacturing concerns. Ocular Surgery News compiled these stories from Healio.com/OSN.The FDA has approved Humira for the treatment of noninfectious intermediate and posterior uveitis and panuveitis, according to a press release from AbbVie. Read more